Correspondence 0001654954-23-002834 from Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc.
Date: March 14, 2023 · CIK: 0001853816 · Accession: 0001654954-23-002834

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-270195

Date

March 13, 2023

Author

DERMATA

Form

CORRESP

Company

Dermata Therapeutics, Inc.

Letter

Re:

drma-accelerationrequestw

March 14, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Dermata Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-270195

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on March 13, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Tuesday, March 14, 2023, at 1:00 p.m., Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 with any questions.

Sincerely,
DERMATA
THERAPEUTICS INC.

Show Raw Text

CORRESP
1
filename1.htm

drma-accelerationrequestw

March
14, 2023

VIA EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100 F
Street, N.E.

Washington,
D.C. 20549

Re:

Dermata Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-270195

Ladies
and Gentlemen:

Reference is made
to our letter, filed as correspondence via EDGAR on March 13, 2023,
in which we requested the acceleration of the effective date of the
above-referenced Registration Statement for Tuesday, March 14,
2023, at 1:00 p.m., Eastern Time, in accordance with Rule 461 under
the Securities Act of 1933, as amended. We are no longer requesting
that such Registration Statement be declared effective at this time
and we hereby formally withdraw our request for acceleration of the
effective date.

Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947
with any questions.

Sincerely,

DERMATA
THERAPEUTICS INC.

By:

/s/
Gerald T. Proehl

Name:

Gerald
T. Proehl

Title:

Chief Executive Officer

SecProbe.io